Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients


23 Nov 2019


Poster display session


Tumour Site

Breast Cancer


Than Than Aye


Annals of Oncology (2019) 30 (suppl_9): ix1-ix8. 10.1093/annonc/mdz416


T.T. Aye1, S. Mon1, M. Khine2, N. Sein2, N.M. Thant2, A.K. Win2, E.P.P. Aung2, P.T. Hnin2

Author affiliations

  • 1 Medical Oncology, Bahosi Medical Centre Bahosi Housing Complex, 11131 - Yangon/MM
  • 2 Medical Oncology, Thurein Mon Clinic, Yangon/MM


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 21P


Due to the limited accessibility of trastuzumab, the majority of Her2 positive breast cancer patients are treated mainly with systemic chemotherapy in Myanmar. This study aimed to find out the clinical outcome of treatment without trastuzumab for Her2 positive breast cancer patients.


A retrospective observational study of total 156 Her2 positive breast cancer patients not receiving anti-her2 therapy who diagnosed between January 2007 and December 2016 in two private oncology centers in Yangon, Myanmar.


In this study, median age of patients was 52 years (25yrs-87yrs). Majority (80%, n = 126) were in early stage. Regarding treatment pattern, 99% of patients underwent either simple or total mastectomy and only 1% was done breast conserving surgery. Anthracycline containing regimes (AC-T or FAC) were given in 99% of patients. Among them, 26% (n = 40) took additional maintenance chemotherapy with oral cyclophosphamide and methotrexate for 3 to 6 months after conventional chemotherapy. After a median follow up of 40 months (8-120), 80% of patients achieved complete response. The median disease free period was 34 months and 3 year invasive disease free survival was 79%. The relapse rate was 17.3%. Lymph nodes (23%) and liver metastases (23%) were the first site of recurrence in relapsed patients. Furthermore, 92% had no recurrence among those received maintenance chemotherapy.


Anthracycline based systemic chemotherapy without anti Her2 therapy showed good clinical outcome in Her2 positive breast cancer patients in real clinical practice in Myanmar.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Medical oncology academic group.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.